25
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Evaluation of an Efavirenz-Containing Regimen: An Open-Label, Multicenter Study

, , , , , , & show all
Pages 421-428 | Published online: 14 Jan 2015

REFERENCES

  • Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med. 1997;337:725–733.
  • Ruiz NM. Clinical history of efavirenz. Int J Clin Pract SuppL 1999;103:3–7.
  • Bartlett J, Demasi R, Quinn J, et al. Meta-analysis of effi-cacy of triple combination therapy in antiretroviral-naive HIV-infected adults. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 519.
  • Murray JS, Elashoff MR, Lacono-Connors LC. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797–804.
  • Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
  • Riddler S, Kahn J, Martin G, et al. Durable HIV suppression and tolerability with efavirenz (ER)) + indinavir (IDV): Resuits at 132 weeks. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 513.
  • Ruiz NM, Bessen LJ, Manion DJ, et al. Potential adverse experiences associated with efavirenz (EFV, SustivaTM) in adults. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31—February 4, 1999; Chicago, IL. Abstract 655.
  • Tashima K, Stryker R, Staszeski S, et al. Lipid profiles and clinical lipodystrophy in Study 006 patients. In: Program and abstracts of the 39th Interscience Conference on Anti-microbial Agents and Chemotherapy; September 26–29, 1999; San Francisco, CA. Abstract 1304.
  • Moyle G, Baldwin C, Dent N, et al. Maintenance of virologi-cal control, changes in clinical lipodystrophy and metabolic parameters in persons switching from PI to efavirenz therapy. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26–29, 1999; San Francisco, CA. Abstract 2064.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.